Display Settings:

Format

Send to:

Choose Destination
Bioorg Med Chem Lett. 2011 Sep 1;21(17):5006-10. doi: 10.1016/j.bmcl.2011.04.128. Epub 2011 May 6.

Modified GM3 gangliosides produced by metabolic oligosaccharide engineering.

Author information

  • 1Division of Translational Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9185, United States.

Abstract

Metabolic oligosaccharide engineering is powerful approach to altering the structure of cellular sialosides. This method relies on culturing cells with N-acetylmannosamine (ManNAc) analogs that are metabolized to their sialic acid counterparts and added to glycoproteins and glycolipids. Here we employed two cell lines that are deficient in ManNAc biosynthesis and examined their relative abilities to metabolize a panel of ManNAc analogs to sialosides. In addition to measuring global sialoside production, we also examined biosynthesis of the sialic acid-containing glycolipid, GM3. We discovered that the two cell lines differ in their ability to discriminate among the variant forms of ManNAc. Further, our data suggest that modified forms of sialic acid may be preferentially incorporated into certain sialosides and excluded from others. Taken together, our results demonstrate that global analysis of sialoside production can obscure sialoside-specific differences. These findings have implications for downstream applications of metabolic oligosaccharide engineering, including imaging and proteomics.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PMID:
21620696
[PubMed - indexed for MEDLINE]
PMCID:
PMC3156312
Free PMC Article

Images from this publication.See all images (4)Free text

Figure 1
Figure 2
Scheme 1
Scheme 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk